Dicerna Pharmaceuticals
Dicerna Pharmaceuticals Inc (Form: 4, Received: 02/04/2014 20:20:21)
FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Flynn James E
2. Issuer Name and Ticker or Trading Symbol

Dicerna Pharmaceuticals Inc [ DRNA ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      __ X __ Other (specify below)
Possible Members of 10% Group
(Last)          (First)          (Middle)

780 THIRD AVENUE, 37TH FLOOR
3. Date of Earliest Transaction (MM/DD/YYYY)

2/4/2014
(Street)

NEW YORK, NY 10017
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   2/4/2014     C    196071   A   (1) 334071   I   (2) Through Deerfield Special Situations Fund, L.P.   (3)
Common Stock   2/4/2014     C    161071   A   (1) 273071   I   (2) Through Deerfield Special Situations International Master Fund, L.P.   (3)
Common Stock   2/4/2014     C    499285   A   (1) 848785   I   (2) Through Deerfield Private Design Fund II, L.P.   (3)
Common Stock   2/4/2014     C    572142   A   (1) 972642   I   (2) Through Deerfield Private Design International II, L.P.   (3)
Common Stock   2/4/2014     P    138000   A $15   334071   I   (2) Through Deerfield Special Situations Fund, L.P.   (3)
Common Stock   2/4/2014     P    112000   A $15   273071   I   (2) Through Deerfield Special Situations International Master Fund, L.P.   (3)
Common Stock   2/4/2014     P    349500   A $15   848785   I   (2) Through Deerfield Private Design Fund II, L.P.   (3)
Common Stock   2/4/2014     P    400500   A $15   972642   I   (2) Through Deerfield Private Design International II, L.P.   (3)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series C Preferred Stock     (1) 2/4/2014     C         196071      (1)   (1) Common Stock   196071     (1) 0   I   (2) Through Deerfield Special Situations Fund, L.P.   (3)
Series C Preferred Stock     (1) 2/4/2014     C         161071      (1)   (1) Common Stock   161071     (1) 0   I   (2) Through Deerfield Special Situations International Master Fund, L.P.   (3)
Series C Preferred Stock     (1) 2/4/2014     C         499285      (1)   (1) Common Stock   499285     (1) 0   I   (2) Through Deerfield Private Design Fund II, L.P.   (3)
Series C Preferred Stock     (1) 2/4/2014     C         572142      (1)   (1) Common Stock   572142     (1) 0   I   (2) Through Deerfield Private Design International II, L.P.   (3)

Explanation of Responses:
( 1)  The Series C Preferred Stock was convertible at any time into the Issuer's Common Stock, on a one-for-one basis and had no expiration date. The Series C Preferred Stock converted into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering of Common Stock.
( 2)  This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons").
( 3)  Deerfield Mgmt, L.P. is the general partner of Deerfield Special Situations Fund, L.P., Deerfield Special Situations International Master Fund, L.P., Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (collectively, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P. and Deerfield Management Company, L.P. In accordance with Instruction 5 (b)(iv) to Form 3, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Remarks:
Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 4 with regard to Talon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 21, 2012 by Deerfield Mgmt L.P., Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P., Deerfield Special Situations Fund International, Limited, Deerfield Private Design Fund, L.P., Deerfield Private Design International, L.P. and James E. Flynn.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Flynn James E
780 THIRD AVENUE
37TH FLOOR
NEW YORK, NY 10017

X
Possible Members of 10% Group
Deerfield Mgmt L.P.
780 THIRD AVENUE
37TH FLOOR
NEW YORK, NY 10017

X
Possible Members of 10% Group
Deerfield Special Situations Fund, L.P.
780 3RD AVENUE
37TH FLOOR
NEW YORK, NY 10017

X
Possible Members of 10% Group
Deerfield Special Situations International Master Fund, L.P.
780 THIRD AVENUE, 37TH FLOOR
NEW YORK, NY 10017

X
Possible Members of 10% Group
Deerfield Private Design Fund II, L.P.
780 THIRD AVENUE, 37TH FLOOR
NEW YORK, NY 10017

X
Possible Members of 10% Group
DEERFIELD MANAGEMENT CO
780 THIRD AVENUE, 37TH FLOOR
NEW YORK, NY 10017

X
Possible Members of 10% Group
Deerfield Private Design International II, Ltd.
780 THIRD AVENUE, 37TH FLOOR
NEW YORK, NY 10017

X
Possible Members of 10% Group

Signatures
/s/ Jonathan Isler 2/4/2014
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Joint Filer Information

Names: 
Deerfield Mgmt, L.P.,  Deerfield Management Company, L.P.,
Deerfield Special Situations Fund, L.P., Deerfield Special Situations International Master Fund, L.P.,
Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P.
 
Address: 
780 Third Avenue, 37 th Floor
New York, NY  10017

Designated Filer:
James E. Flynn

Issuer and Ticker Symbol:
Dicerna Pharmaceuticals, Inc. [DRNA]

Date of Event Requiring Statement:
February 4, 2014
 
The undersigned, Deerfield Mgmt, L.P.,  Deerfield Management Company, L.P., Deerfield Special Situations Fund, L.P., Deerfield Special Situations International Master Fund, L.P., Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. are jointly filing the attached Statement of Changes in Beneficial Ownership on Form 4 with James E. Flynn with respect to the beneficial ownership of securities of Dicerna Pharmaceuticals, Inc.

Signatures:

DEERFIELD MGMT, L.P.

By:  J.E. Flynn Capital LLC, General Partner

By: /s/ Jonathan Isler
       Jonathan Isler, Attorney-in-Fact


DEERFIELD MANAGEMENT COMPANY, L.P.
 
By:  Flynn Management LLC, General Partner

By: /s/ Jonathan Isler
       Jonathan Isler, Attorney-in-Fact
 
 
DEERFIELD SPECIAL SITUATIONS FUND, L.P.

By:  Deerfield Mgmt, L.P., General Partner

By:  J.E. Flynn Capital LLC, General Partner

By: /s/ Jonathan Isler
       Jonathan Isler, Attorney-in-Fact
 
 
 

 

 
DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P.

By:  Deerfield Mgmt, L.P., General Partner

By:  J.E. Flynn Capital LLC, General Partner

By: /s/ Jonathan Isler
       Jonathan Isler, Attorney-in-Fact


DEERFIELD PRIVATE DESIGN FUND II, L.P.

By:  Deerfield Mgmt, L.P., General Partner

By:  J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler
       Jonathan Isler, Attorney-in-Fact


DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.
 
By:  Deerfield Mgmt, L.P., General Partner

By:  J.E. Flynn Capital, LLC, General Partner
 
By: /s/ Jonathan Isler
       Jonathan Isler, Attorney-in-Fact